Use

The NTRK NGS Fusion Panel is an RNA‑based next‑generation sequencing assay designed to detect translocations and fusions involving the Neurotrophic Tropomyosin‑Related Kinase genes NTRK1, NTRK2, and NTRK3 with both known and novel fusion partners, as well as selected point mutations in specific exons of these genes. It is intended to guide therapy selection based on FDA‑approved TRK inhibitors such as ROZLYTREK® (entrectinib) and VITRAKVI® (larotrectinib).